Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract: The present invention provides a crystal of the extracellular domain of mammalian DPP-IV, wherein the crystal has an orthorhombic space group of P212121 and one homodimer of DPP-IV in the asymmetric unit. Also provided is a co-crystal which includes a ligand bound to the active site of mammalian DPP-IV. The invention permits the identification or design of inhibitor compounds of DPP-IV activity, for use in treatment of type II diabetes.

Abstract: The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.

Abstract: The present invention provides a crystal of the extracellular domain of mammalian DPP-IV, wherein the crystal has an orthorhombic space group of P212121 and one homodimer of DPP-IV in the asymmetric unit. Also provided is a co-crystal which includes a ligand bound to the active site of mammalian DPP-IV. The invention permits the identification or design of inhibitor compounds of DPP-IV activity, for use in treatment of type II diabetes.

Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.

Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract: A method is described for control of a CVT automatic transmission (1) in which a sensed main pressure (p_hd_act) and a sensed contact pressure (p_s2_act) of a secondary pulley (7) are entered as signals in an electronic transmission control (8). For diagnosis of an error in the sensing of the main pressure (p_hd_act) and/or of the contact pressure (p_s2_act) of the secondary pulley (7) their actual values or comparison variable (|p_hd_act-p_hd_nom|, |p_s2_act-p_s2_nom|) formed therefrom are compared with applicable threshold values (p_hd_min, pd_phd_regdiff, p_s2_min, pd_ps2_regdiff) associated with a range of plausible pressure values.

Abstract: Engine torque control system based on the dynamic behavior of a driven automatic transmission consists in that the engine dynamics is limited as function of a sporting mode.

Abstract: Within the scope of the process for variator slip treatment in continuously variable automatic transmissions of a motor vehicle, upon detection of variator slip, a characteristic field (1) of slip meter is locally incremented according to ratio value (iv) and to engine torque (M_mot) and simultaneously an evaluated slip meter (2) of an evaluation module (3), likewise according to ratio value (iv) and to engine torque (M_mot), is increased, wherein via the evaluation module (3), the variator slip is assessed according to duration and intensity. Besides, a characteristic field (4) of slip status meter connected with the evaluated slip meter (2) is incremented together with the evaluated slip meter (2), a signal being passed on to an error memory (5) so that, with the entry of the error, slip, evaluated slip and slip status meter are entered in the error memory (5) as environmental conditions.